SUN PHARMACEUTICAL INDUSTRIES, INC.

Lobbying client · New Jersey · filed 2025 to 2026

Biopharmaceutical manufacturer.

$620,000 Reported spend

12 Filings counted

2 Outside firms hired

3 Bills named

Spend is reported income plus in-house expenses across 12 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 3 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

Who filed for this client 3

FIERCE GOVERNMENT RELATIONS $320,000 Outside firm · 6 filings
MARSHALL & POPP, LLC $160,000 Outside firm · 4 filings
SUN PHARMACEUTICAL INDUSTRIES, INC. $140,000 In-house, the client's own filings · 2 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 3

H.R. 5526
Biosimilar Red Tape Elimination Act

1 filing
S. 1414
Expedited Access to Biosimilars Act

1 filing
S. 2658
Medication Affordability and Patent Integrity Act

1 filing

Reported by year 2 years

2026 $380,000 8 filings
2025 $240,000 4 filings

Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 6

HOUSE OF REPRESENTATIVES 4
SENATE 4
Centers For Medicare and Medicaid Services (CMS) 3
Food & Drug Administration (FDA) 3
Health & Human Services, Dept of (HHS) 3
Commerce, Dept of (DOC) 1

Recent filings 12 total

Q3 report

MARSHALL & POPP, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026

View → Q3 report

SUN PHARMACEUTICAL INDUSTRIES, INC.

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $140,000 expenses · posted Oct 20, 2026

View → Q2 terminationNo activity

FIERCE GOVERNMENT RELATIONS

2nd Quarter 2026 (Apr 1 - June 30) · $20,000 income · posted Jul 20, 2026

View → Q2 report

MARSHALL & POPP, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 9, 2026

View → Registration

SUN PHARMACEUTICAL INDUSTRIES, INC.

3rd Quarter 2026 (July 1 - Sep 30) · posted Jul 7, 2026

View → Q1 reportNo activity

FIERCE GOVERNMENT RELATIONS

1st Quarter 2026 (Jan 1 - Mar 31) · $60,000 income · posted Apr 20, 2026

View → Q1 report

MARSHALL & POPP, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $40,000 income · posted Apr 17, 2026

View → Registration

MARSHALL & POPP, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · posted Feb 24, 2026

View → Q4 reportNo activity

FIERCE GOVERNMENT RELATIONS

4th Quarter 2025 (Oct 1 - Dec 31) · $60,000 income · posted Jan 20, 2026

View → Q3 reportNo activity

FIERCE GOVERNMENT RELATIONS

3rd Quarter 2025 (July 1 - Sep 30) · $60,000 income · posted Oct 17, 2025

View → Q2 reportNo activity

FIERCE GOVERNMENT RELATIONS

2nd Quarter 2025 (Apr 1 - June 30) · $60,000 income · posted Jul 21, 2025

View → Q1 reportNo activity

FIERCE GOVERNMENT RELATIONS

1st Quarter 2025 (Jan 1 - Mar 31) · $60,000 income · posted Apr 18, 2025

View →

Foreign entities disclosed 4

SHANGHVI FINANCE PRIVATE LIMITED India named on 1 filing · highest disclosed ownership 40.30% · largest disclosed contribution $0
SUN PHARMACEUTICAL INDUSTRIES LIMITED India named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0
SUN PHARMA HOLDINGS UK LTD. United Kingdom named on 1 filing · highest disclosed ownership 96.35% · largest disclosed contribution $0
SUN PHARMA (NETHERLANDS) B.V. Netherlands named on 1 filing · highest disclosed ownership 96.35% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.